Long‐term postoperative effects of administration of allogeneic blood products in 104 dogs with hemangiosarcoma

Abstract

Objective To determine the influence of administering allogeneic blood products (ABP) on the progression of hemangiosarcoma in dogs. Study design Multi‐institutional, retrospective study. Sample population One hundred four dogs with hemangiosarcoma that survived until postoperative discharge from the hospital. Methods Medical records of dogs that had been operated on for hemoangiosarcoma were reviewed for signalment, presence of a hemoabdomen, presence of metastatic disease, and whether the dog had received chemotherapy or Yunnan Baiyao. Data that were collected were compared between dogs that received perioperative ABP and those that did not. Disease‐free interval was compared between groups. The Kaplan‐Meier method was used to obtain univariate descriptive statistics for time to clinical decline. A multivariable Cox regression model was used to analyze association or effect of potential predictor variables. Results The median disease‐free interval (DFI) was shorter in the 67 dogs that received a blood transfusion (76 days; range, 1‐836) than in the 37 dogs that did not receive a blood transfusion (120 days; range, 38‐916). According to the multivariable Cox regression model, administration of blood products (P = .04) and the presence of gross metastatic disease at the time of surgery (P < .01) shortened the DFI, whereas administration of Yunnan Baiyao (P = .01) prolonged the DFI. Conclusion Allogeneic blood product administration was associated with a shorter disease‐free interval in this population. However, we could not demonstrate the association between blood products and shorter DFI because of confounding factors. Clinical significance Dogs that receive ABP at the time of surgical therapy for hemangiosarcoma may have accelerated disease progression compared with dogs that do not receive ABP.

Timely adjuvant chemotherapy improves outcome in dogs with non‐metastatic splenic hemangiosarcoma undergoing splenectomy

“…In the present study, median StoC was 20 days; this is in line with a recent study by Finotello et al, 31 whereas two studies reported shorter times 1,25 . This relatively long interval may be due to several reasons.…”

“…In dogs, hemangiosarcoma (HSA) is a common and aggressive cancer of vascular origin. The spleen is the most common primary site, with nearly 50% of dogs having evidence of metastatic disease at presentation 1,2 . Splenectomy as the sole treatment modality is considered palliative; the addition of adjuvant doxorubicin‐based chemotherapy usually only increases the average survival time by 2–4 months 3–5 …”

“…The spleen is the most common primary site, with nearly 50% of dogs having evidence of metastatic disease at presentation. 1,2 Splenectomy as the sole treatment modality is considered palliative; the addition of adjuvant doxorubicin-based chemotherapy usually only increases the average survival time by 2-4 months. [3][4][5] There is accumulating evidence that surgical resection may enhance metastatic shedding of tumour cells.…”

Outcomes and Blood Product Use in 89 Surgically Managed and 79 Medically Managed Cases of Acute Spontaneous Hemoperitoneum in the Dog

“…Furthermore, transfusion related immunomodulation (TRIM) is a recently described consequence of allogenic blood product administration in man, although the exact mechanism by which this phenomenon occurs remains to be determined (33). TRIM may have as yet unknown implications in the veterinary field, and a recent study investigating long-term postoperative effects of administration of allogeneic blood products in dogs with hemangiosarcoma concluded that dogs administered allogenic blood products had a shorter disease-free interval than dogs that did not (34). For these reasons, avoidance of allogenic blood products may be of benefit in those patients that are able to be stabilized without the need for transfusions.…”

Hepatic Hemangiosarcoma in a Cynomolgus Macaque (Macaca fascicularis)

“…12 A recent study in 104 canine patients with hemangiosarcoma indicated that administration of blood products and the presence of gross metastatic disease at the time of surgery shortened the disease-free interval, whereas administration of the Chinese herbal supplement Yunnan Baiyao prolonged the disease-free interval. 8 To confirm findings, immunohistochemistry was performed using endothelial cell immunomarkers that were selected due to their widely-accepted use in the diagnosis of hemangiosarcoma. CD31, also known as PECAM1 (platelet endothelial cell adhesion molecule 1), is a glycoprotein that is expressed on endothelial cells, platelets, and leukocytes and is involved many physiologic and pathologic pathways, including leukocyte migration, angiogenesis, maintenance of vascular integrity, and immunoregulatory roles in endothelial and hematopoietic cells.…”